Delivery Order SPE2DB22D3501-SPE2DB25FUA11

Award Date 1/2/25
Potential Completion Date 1/3/25
Potential Value $3.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 15 MG TABLET in the amount of $15,194.85. The delivery order has a firm fixed price and an ultimate completion date of June 6, 2024. AmerisourceBergen holds a large Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which serves as the primary vehicle for providing a comprehensive range...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 15 MG TABLET UU 30S. The delivery order has a ceiling value of $24,498.72 and a completion date of July 18, 2024. The contract is a firm fixed-price delivery order and does not have a set-aside designation. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $25,092.28, is for the supply of RINVOQ ER 15 MG TABLET UU 30S, a pharmaceutical product. The contract has a firm fixed price pricing type and an ultimate completion date of October 22, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of RINVOQ ER 15 MG TABLET, a pharmaceutical product, with a total ceiling value of $31,638.05 and a period of performance through March 19, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 15 mg tablets. The firm-fixed-price contract, valued at $8,523.61, has an ultimate completion date of September 24, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of the pharmaceutical product RINVOQ ER 30 MG TABLET UU 30S. The contract has a ceiling value of $36,092.52 and an ultimate completion date of September 16, 2024. The contract is not designated as a set-aside. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous Indefinite Delivery Contracts (IDCs) by federal agencies, including a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 MG TABLET UU 30S, a prescription medication. The contract has a ceiling value of $43,710.66 and an ultimate completion date of July 19, 2024. AmerisourceBergen, a major pharmaceutical distributor, holds several Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies to provide a wide range of medical commodities, including pharmaceuticals,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $13,496.63 and covers the supply of RINVOQ ER 15 MG TABLET (30 count). It is a Firm Fixed Price contract with a period of performance through August 16, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...
This is a $49,941.35 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 15 MG TABLET. The contract has an ultimate completion date of August 6, 2024 and is not set aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025 for delivering a comprehensive range of...
This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $6,223.32 firm fixed-price contract provides RINVOQ ER 15 MG TABLET UU 30S, a specialty pharmaceutical product, to support military healthcare programs. The contract has an ultimate completion date of December 31, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FUA11
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RINVOQ ER 30 MG TABLET UU 30S. The contract has a ceiling value of $3,111.66 and a completion date of January 3, 2025. It is a firm fixed-price contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 4/3/25, 11:03 AM